Recent advances and limitations in the application of kahalalides for the control of cancer
Year: 2022
Type: review
Abstract: Since the discovery of the kahalalide family of marine depsipeptides in 1993, considerable work has been done to develop these compounds as new and biologically distinct anti-cancer agents. Clinical trials and laboratory research have yielded a wealth of data that indicates tolerance of kahalalides in healthy cells and selective activity against diseased cells. Currently, two molecules have attracted the greates level of attention, kahalalide F (KF) and isokahalalide F (isoKF, Irvalec, PM 02734, elisidepsin). Both compounds were originally isolated from the sarcoglossan mollusk Elysia rufescens but due to distinct structural characteristics it has been hypothesized and recently shown that the ultimate origin of the molecules is microbial. The search for their true source has been a subject of considerable research in the anticipation of finding new analogs and a culturable expression system that can produce sufficient material through fermentation to be industrially relevant.
Source: Biomedicine & Pharmacotherapy
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,740
Awards: South Carolina IDeA Networks of Biomedical Research Excellence (SC INBRE), South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling, Epithelial adherens junctions regulate colon cell behavior through RNAi and lncRNAs, PIWI - Transposon regulation by epithelial adherens junctions, G9000233351, G9000355285, MUSC Digestive Disease Research Core Center
OpenAlex ID: W4211147830